Bochner F, Hooper W D, Tyrer J H, Eadie M J
J Neurol Neurosurg Psychiatry. 1972 Dec;35(6):873-6. doi: 10.1136/jnnp.35.6.873.
Blood phenytoin (diphenylhydantoin) concentrations were measured after each dosage change in 12 epileptic patients who were given increasing oral doses of phenytoin. In each of these patients a dosage increment beyond the dosage that produced a blood phenytoin level of 6-9 μg/ml. caused a disproportionately great increase in the blood concentration of drug. This effect might be expected if the limit of the body's capacity to metabolize phenytoin were being reached. As oral dosages were increased in one patient, measurements of the rate of urinary excretion of phenytoin metabolite showed that the phase of rapid rise in blood phenytoin concentration coincided with a failure to increase the rate of phenytoin metabolite excretion. Awareness of the non-linear relation between oral dose and blood concentration of phenytoin in the individual patient, and realization that the phase of rapid rise in blood phenytoin concentration occurs through the `therapeutic' range of 10-20 μg/ml., is of importance to those who use blood phenytoin levels as a guide to the adequacy of anticonvulsant therapy.
对12例癫痫患者口服苯妥英剂量递增后,每次剂量改变后均测定血苯妥英(二苯乙内酰脲)浓度。在这些患者中,当血苯妥英水平达到6 - 9μg/ml后再增加剂量,会导致血药浓度不成比例地大幅升高。如果达到了机体代谢苯妥英能力的极限,可能会出现这种效应。在一名患者口服剂量增加时,对苯妥英代谢产物的尿排泄率进行测量,结果显示血苯妥英浓度快速上升阶段与苯妥英代谢产物排泄率未能增加相吻合。了解个体患者口服剂量与血苯妥英浓度之间的非线性关系,并认识到血苯妥英浓度快速上升阶段会经过10 - 20μg/ml的“治疗”范围,对于那些将血苯妥英水平作为抗惊厥治疗充分性指导的人来说非常重要。